160 related articles for article (PubMed ID: 28969371)
1. Mammalian target of rapamycin complex 1 activation sensitizes human glioma cells to hypoxia-induced cell death.
Thiepold AL; Lorenz NI; Foltyn M; Engel AL; Divé I; Urban H; Heller S; Bruns I; Hofmann U; Dröse S; Harter PN; Mittelbronn M; Steinbach JP; Ronellenfitsch MW
Brain; 2017 Oct; 140(10):2623-2638. PubMed ID: 28969371
[TBL] [Abstract][Full Text] [Related]
2. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
3. Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells.
Sun Y; Gu X; Zhang E; Park MA; Pereira AM; Wang S; Morrison T; Li C; Blenis J; Gerbaudo VH; Henske EP; Yu JJ
Cell Death Dis; 2014 May; 5(5):e1231. PubMed ID: 24832603
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Strategy for Targeting Aggressive Malignant Gliomas by Disrupting Their Energy Balance.
Hegazy AM; Yamada D; Kobayashi M; Kohno S; Ueno M; Ali MA; Ohta K; Tadokoro Y; Ino Y; Todo T; Soga T; Takahashi C; Hirao A
J Biol Chem; 2016 Oct; 291(41):21496-21509. PubMed ID: 27519418
[TBL] [Abstract][Full Text] [Related]
5. Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment.
Heinzen D; Divé I; Lorenz NI; Luger AL; Steinbach JP; Ronellenfitsch MW
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31510109
[TBL] [Abstract][Full Text] [Related]
6. Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamide.
Parkhitko AA; Priolo C; Coloff JL; Yun J; Wu JJ; Mizumura K; Xu W; Malinowska IA; Yu J; Kwiatkowski DJ; Locasale JW; Asara JM; Choi AM; Finkel T; Henske EP
Mol Cancer Res; 2014 Jan; 12(1):48-57. PubMed ID: 24296756
[TBL] [Abstract][Full Text] [Related]
7. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions.
Kaper F; Dornhoefer N; Giaccia AJ
Cancer Res; 2006 Feb; 66(3):1561-9. PubMed ID: 16452213
[TBL] [Abstract][Full Text] [Related]
8. Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death.
Ronellenfitsch MW; Brucker DP; Burger MC; Wolking S; Tritschler F; Rieger J; Wick W; Weller M; Steinbach JP
Brain; 2009 Jun; 132(Pt 6):1509-22. PubMed ID: 19416948
[TBL] [Abstract][Full Text] [Related]
9. p53 Deletion or Hotspot Mutations Enhance mTORC1 Activity by Altering Lysosomal Dynamics of TSC2 and Rheb.
Agarwal S; Bell CM; Taylor SM; Moran RG
Mol Cancer Res; 2016 Jan; 14(1):66-77. PubMed ID: 26385560
[TBL] [Abstract][Full Text] [Related]
10. Post-translational regulation of mTOR complex 1 in hypoxia and reoxygenation.
Tan CY; Hagen T
Cell Signal; 2013 May; 25(5):1235-44. PubMed ID: 23416465
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of cytochrome C oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death.
Wanka C; Brucker DP; Bähr O; Ronellenfitsch M; Weller M; Steinbach JP; Rieger J
Oncogene; 2012 Aug; 31(33):3764-76. PubMed ID: 22120717
[TBL] [Abstract][Full Text] [Related]
12. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia sensitizes human malignant glioma cells towards CD95L-induced cell death.
Steinbach JP; Wolburg H; Klumpp A; Weller M
J Neurochem; 2005 Mar; 92(6):1340-9. PubMed ID: 15748153
[TBL] [Abstract][Full Text] [Related]
14. FOXO3a orchestrates glioma cell responses to starvation conditions and promotes hypoxia-induced cell death.
Brucker DP; Maurer GD; Harter PN; Rieger J; Steinbach JP
Int J Oncol; 2016 Dec; 49(6):2399-2410. PubMed ID: 27840901
[TBL] [Abstract][Full Text] [Related]
15. Loss of Tsc1 accelerates malignant gliomagenesis when combined with oncogenic signals.
Yamada D; Hoshii T; Tanaka S; Hegazy AM; Kobayashi M; Tadokoro Y; Ohta K; Ueno M; Ali MA; Hirao A
J Biochem; 2014 Apr; 155(4):227-33. PubMed ID: 24368778
[TBL] [Abstract][Full Text] [Related]
16. NFκB up-regulation of glucose transporter 3 is essential for hyperactive mammalian target of rapamycin-induced aerobic glycolysis and tumor growth.
Zha X; Hu Z; Ji S; Jin F; Jiang K; Li C; Zhao P; Tu Z; Chen X; Di L; Zhou H; Zhang H
Cancer Lett; 2015 Apr; 359(1):97-106. PubMed ID: 25578782
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA148b-3p inhibits mTORC1-dependent apoptosis in diabetes by repressing TNFR2 in proximal tubular cells.
Kuwagata S; Kume S; Chin-Kanasaki M; Araki H; Araki S; Nakazawa J; Sugaya T; Koya D; Haneda M; Maegawa H; Uzu T
Kidney Int; 2016 Dec; 90(6):1211-1225. PubMed ID: 27591086
[TBL] [Abstract][Full Text] [Related]
18. High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting.
Medvetz D; Sun Y; Li C; Khabibullin D; Balan M; Parkhitko A; Priolo C; Asara JM; Pal S; Yu J; Henske EP
Mol Cancer Res; 2015 Jan; 13(1):50-62. PubMed ID: 25185584
[TBL] [Abstract][Full Text] [Related]
19. mTORC1 is involved in hypoxia-induced pulmonary hypertension through the activation of Notch3.
Wang W; Liu J; Ma A; Miao R; Jin Y; Zhang H; Xu K; Wang C; Wang J
J Cell Physiol; 2014 Dec; 229(12):2117-25. PubMed ID: 24825564
[TBL] [Abstract][Full Text] [Related]
20. Tuberous Sclerosis Complex Protein 2-Independent Activation of mTORC1 by Human Cytomegalovirus pUL38.
Bai Y; Xuan B; Liu H; Zhong J; Yu D; Qian Z
J Virol; 2015 Aug; 89(15):7625-35. PubMed ID: 25972538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
